Search

Your search keyword '"Kurt A. Dreger"' showing total 13 results
Start Over Author "Kurt A. Dreger"
13 results on '"Kurt A. Dreger"'

1. Use of immunosuppression and subsequent cancer incidence: cohort study

Author

Naira Khachatryan, Gui-Shuang Ying, James T Rosenbaum, Gary N Holland, Maxwell Pistilli, John H. Kempen, Nisha R Acharya, Debra A Goldstein, John H Kempen, Ebenezer Daniel, Jennifer E Thorne, Careen Y Lowder, Teresa L Liesegang, Eric B Suhler, Grace A Levy-Clarke, Robert B Nussenblatt, Tracy Giles, RUSSELL W READ, Yannek I Leiderman, Craig W Newcomb, Nirali P Bhatt, James P Dunn, Asaf Hanish, Kathy J Helzlsouer, Siddharth S Pujari, Teresa Liesegang, Lucia Sobrin, Hosne Begum, Pichaporn Artornsombudh, Jeanine M Buchanich, Terri L Washington, Charles Stephen Foster, Douglas Alan Jabs, Hatice Nida Sen, Kurt A Dreger, Hosne A Begum, Tonetta D Fitzgerald, Srishti Kothari, Abhishek R Payal, Sapna S Gangaputra, Roje Oktay Kaçmaz, Armin Maghsoudlou, Hilkiah K Suga, Clara M Pak, Hilkiah K. Suga, John Caccaviello, C. Stephen Foster, R. Oktay Kaçmaz, Siddharth S. Pujari, Abhishek Payal, Jennifer E. Thorne, Douglas A. Jabs, Kurt A. Dreger, James P. Dunn, Sapna S. Gangaputra, Eric B. Suhler, James T. Rosenbaum, H. Nida Sen, Grace A. Levy-Clarke, Robert B. Nussenblatt, Nirali P. Bhatt, Tonetta D. Fitzgerald, Kathy J. Helzlsouer, Marshall M. Joffe, Jeanine M. Buchanich, Terri L. Washington, Careen Y. Lowder, Gary N. Holland, Nisha R. Acharya, Yannek I. Liederman, Jie Debra A. Goldstein, Debra A. Goldstein, Jie (Jessica) Sun, Russell W. Read, Glenn J. Jaffe, Paul A. Latkany, Janet L. Davis, and Sunir J. Garg

Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Objective Evaluate the association between cancer incidence and immunosuppressive treatment in patients with ocular inflammatory disease (OID).Methods and analysis We performed a retrospective cohort study of patients from 10 US OID subspecialty practices. Patients with non-infectious OID were included; HIV-infected patients were excluded. Time-dependent exposure to drug classes (ie, antimetabolites, calcineurin inhibitors, alkylating agents, tumour necrosis factor (TNF) inhibitors) and drugs were evaluated. Cancer incidence was ascertained by linkage to 12 state cancer registries from 1996 to 2015. Cancer incidence was analysed using Cox regression survival analysis, using 0-year, 3-year and 5-year lags after immunosuppression began.Results The cancer incidence cohort comprised 10 872 individuals at risk of incident cancer and residing in one of the 12 states covered; 812 primary cancers were identified through cancer incidence tracing with median follow-up time of 10 years. Neither TNF inhibitor, antimetabolite, calcineurin inhibitor nor alkylating agent classes were associated with statistically significant increases in cancer incidence adjusting for covariates. We found statistically significant reduced hazards in the systemic inflammatory disease (SID)-including cohort for adalimumab and chlorambucil, increased hazards for tacrolimus and etanercept in the non-SID cohort and reduced hazards for methotrexate in both. Other immunosuppressive drugs were not associated with overall cancer incidence.Conclusions We found no increased risk of overall or site-specific cancer incidence associated with short-term (non-transplant) therapy with most commonly used immunosuppressive drug classes and many specific drugs. Further research may clarify potentially protective or harmful effects of specific agents that were not consistently associated with reduced or increased cancer incidence.Trial registration number NCT00116090.

Published
2023
Full Text
View/download PDF

2. Educating for OSHA Savvy Chemists

Author

PAUL J. UTTERBACK, DAVID A. NELSON, Paul J. Utterback, David A. Nelson, Andrea Sutherland, Norman J. Van Houten, Russell W. Phifer, R. B. Schwartz, Richard J. Giszezak, Kurt W. Dreger, Steven F. Pedersen, R. Vernon Clark, J. G. Palmer, George H. Wahl, David Rainer, Gordon J. Miller, Paul Richmond, E

Published
1998

3. Tort Law

Author

Kurt W. Dreger

Published
2018

12. Remission of Intermediate Uveitis: Incidence and Predictive Factors

Author

John H. Kempen, Dina Y. Gewaily, Craig W. Newcomb, Teresa L. Liesegang, R. Oktay Kaçmaz, Grace A. Levy-Clarke, Robert B. Nussenblatt, James T. Rosenbaum, H. Nida Sen, Eric B. Suhler, Jennifer E. Thorne, C. Stephen Foster, Douglas A. Jabs, Abhishek Payal, Tonetta D. Fitzgerald, Marshall M. Joffe, Kurt A. Dreger, Maxwell Pistilli, Srishti Kothari, Naira Khacharyan, Pichaporn Artornsombudh, Asaf Hanish, Sapna S. Gangaputra, Hosne Begum, Ebenezer Daniel, James P. Dunn, Kathy J. Helzlsouer, Siddharth S. Pujari, Teresa Liesegang, Jeanine Buchanich, and Terri L. Washington

Subjects
Pars plana, Adult, Male, medicine.medical_specialty, Adolescent, Remission, Spontaneous, Spontaneous remission, Article, Cohort Studies, 03 medical and health sciences, 0302 clinical medicine, Risk Factors, Internal medicine, medicine, Humans, 030212 general & internal medicine, Retrospective Studies, business.industry, Incidence (epidemiology), Incidence, Hazard ratio, Retrospective cohort study, Middle Aged, medicine.disease, Surgery, Ophthalmology, medicine.anatomical_structure, 030221 ophthalmology & optometry, Intermediate uveitis, Female, business, Uveitis, Intermediate, Uveitis, Cohort study, Follow-Up Studies
Abstract

To evaluate the incidence of remission among patients with intermediate uveitis; to identify factors potentially predictive of remission.Retrospective cohort study.Involved eyes of patients with primary noninfectious intermediate uveitis at 4 academic ocular inflammation subspecialty practices, followed sufficiently long to meet the remission outcome definition, were studied retrospectively by standardized chart review data. Remission of intermediate uveitis was defined as a lack of inflammatory activity at ≥2 visits spanning ≥90 days in the absence of any corticosteroid or immunosuppressant medications. Factors potentially predictive of intermediate uveitis remission were evaluated using survival analysis.Among 849 eyes (of 510 patients) with intermediate uveitis followed over 1934 eye-years, the incidence of intermediate uveitis remission was 8.6/100 eye-years (95% confidence interval [CI], 7.4-10.1). Factors predictive of disease remission included prior pars plana vitrectomy (PPV) (hazard ratio [HR] [vs no PPV] = 2.39; 95% CI, 1.42-4.00), diagnosis of intermediate uveitis within the last year (HR [vs diagnosis5 years ago] =3.82; 95% CI, 1.91-7.63), age ≥45 years (HR [vs age45 years] = 1.79; 95% CI, 1.03-3.11), female sex (HR = 1.61; 95% CI, 1.04-2.49), and Hispanic race/ethnicity (HR [vs white race] = 2.81; 95% CI, 1.23-6.41). Presence/absence of a systemic inflammatory disease, laterality of uveitis, and smoking status were not associated with differential incidence.Our results suggest that intermediate uveitis is a chronic disease with an overall low rate of remission. Recently diagnosed patients and older, female, and Hispanic patients were more likely to remit. With regard to management, pars plana vitrectomy was associated with increased probability of remission.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results